Predictors of Failed Thrombolysis in Acute Myocardial Infarction
Launched by OSLO UNIVERSITY HOSPITAL · Apr 20, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying why some patients with a serious heart condition called ST-segment elevation myocardial infarction (STEMI) do not respond well to a treatment known as thrombolysis. Thrombolysis uses a medication called tissue-plasminogen activator (t-PA) to help dissolve blood clots that block blood flow to the heart. Researchers at Oslo University Hospital Ullevål will look at 200 patients who received this treatment before arriving at the hospital. They will take a blood sample right away to measure certain factors in the blood that might help explain why the treatment works for some patients but not for others.
Anyone over 18 years old who has been diagnosed with STEMI and has already received thrombolysis is eligible to participate in the study. There are no specific exclusions based on age or other health conditions. Participants can expect to provide a blood sample for analysis, and the findings from this study could help doctors better understand how to improve treatment for future patients with similar conditions. This research is ongoing, and your involvement could contribute to important advancements in heart care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • STEMI patients \> 18 years given prehospital thrombolysis.
- Exclusion Criteria:
- • None.
About Oslo University Hospital
Oslo University Hospital is a leading academic medical center in Norway, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital integrates cutting-edge scientific inquiry with patient care, fostering an environment that promotes the development of new therapies and treatment strategies. With a multidisciplinary approach, Oslo University Hospital collaborates with various stakeholders, including researchers, healthcare professionals, and industry partners, to enhance clinical outcomes and contribute to the global medical community. Its dedication to ethical standards and patient safety ensures that all trials are conducted with the highest level of integrity and respect for participant welfare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oslo, , Norway
Patients applied
Trial Officials
Ragnhild Helseth, MD PhD
Study Director
Department of Cardiology, Oslo University Hospital Ullevål
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials